Catalog No.
VHK25301
Species reactivity
Human
Host species
Human
Isotype
IgG1, kappa
Clonality
Monoclonal
Applications
Neutralization
Target
CD16, CD32, Low affinity immunoglobulin gamma Fc region receptor III, IgG Fc receptor III, Fc-gamma RIII, FcRIII, CD16, Fcgr3, Low affinity immunoglobulin gamma Fc region receptor II, Fc gamma receptor IIB, Fc-gamma RII, Fc-gamma-RIIB, FcRII, IgG Fc receptor II beta, Lymphocyte antigen 17, Ly-17, CD32, Fcgr2, Fcgr2b, Ly-17
Concentration
2.93 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Clone ID
Iv0017
Note
For research use only. Not suitable for clinical or therapeutic use.
The novel high-affinity humanized antibody IMM40H targets CD70, eliminates tumors via Fc-mediated effector functions, and interrupts CD70/CD27 signaling., PMID:37849799
Targeting the aryl hydrocarbon receptor (AhR) with BAY 2416964: a selective small molecule inhibitor for cancer immunotherapy., PMID:37963637
A novel single domain bispecific antibody targeting VEGF and TNF-α ameliorates rheumatoid arthritis., PMID:37992444
The anti-B7-H3 blocking antibody MJ18 does not recognize B7-H3 in murine tumor models., PMID:38014341
Targeting transforming growth factor beta signaling in metastatic osteosarcoma., PMID:38021074
The anticancer application of half-sandwich iridium(III) ferrocene-thiosemicarbazide Schiff base complexes., PMID:38054240
Fcγ receptors and immunomodulatory antibodies in cancer., PMID:38062252
A nanobody inhibiting porcine reproductive and respiratory syndrome virus replication via blocking self-interaction of viral nucleocapsid protein., PMID:38084961
A highly potent anti-VISTA antibody KVA12123 - a new immune checkpoint inhibitor and a promising therapy against poorly immunogenic tumors., PMID:38152397
Administration of an AAV vector coding for a P2X7-blocking nanobody-based biologic ameliorates colitis in mice., PMID:38212782
Dual-modality probe nanodrug delivery systems with ROS-sensitivity for atherosclerosis diagnosis and therapy., PMID:38230621
Leukocyte-associated immunoglobulin-like receptor-1 blockade in combination with programmed death-ligand 1 targeting therapy mediates increased tumour control in mice., PMID:38236251
JAGGER localization and function are dependent on GPI anchor addition., PMID:38294499
mIgM-mediated splenic marginal zone B cells targeting of folic acid for immunological evasion., PMID:38322341
IgG hexamers initiate acute lung injury., PMID:38328049
Human Fc gamma receptor IIIA blockade inhibits platelet destruction in a humanized murine model of ITP., PMID:38330193
Development of a Bispecific IgG1 Antibody Targeting BCMA and PDL1., PMID:38390876
Rapid unleashing of macrophage efferocytic capacity via transcriptional pause release., PMID:38480883
C1q enables influenza hemagglutinin stem binding antibodies to block viral attachment and broadens the antibody escape repertoire., PMID:38517951
IgG hexamers initiate complement-dependent acute lung injury., PMID:38530369
Characterization of a novel anti-PVRIG antibody with Fc-competent function that exerts strong antitumor effects via NK activation in preclinical models., PMID:38554184
Aspecific binding of anti-NK1.1 antibodies on myeloid cells in an experimental model for malaria-associated acute respiratory distress syndrome., PMID:38637828
Human coronavirus OC43 nanobody neutralizes virus and protects mice from infection., PMID:38709106
Targeting CEACAM5-positive solid tumors using NILK-2401, a novel CEACAM5xCD47 κλ bispecific antibody., PMID:38720892
Promising Effects of Casearins in Tumor-Bearing Mice and Antinociceptive Action against Oncologic Pain: Molecular Docking and In Vivo Findings., PMID:38794204
Enhanced IL-15-mediated NK cell activation and proliferation by an ADAM17 function-blocking antibody involves CD16A, CD137, and accessory cells., PMID:38798522
[A recombinant adeno-associated virus expressing secretory TGF-β type Ⅱ receptor inhibits triple-negative murine breast cancer 4T1 cell proliferation and lung metastasis in mice]., PMID:38862439
Enhancing Neutrophil Cytotoxicity of a Panel of Clinical EGFR Antibodies by Fc Engineering to IgA3.0., PMID:38958494
Combining CD38 antibody with CD47 blockade is a promising strategy for treating hematologic malignancies expressing CD38., PMID:38983860
Cell-cell contact-dependent secretion of large-extracellular vesicles from EFNBhigh cancer cells accelerates peritoneal dissemination., PMID:39003372
The relevance of tumor target expression levels on IgA-mediated cytotoxicity in cancer immunotherapy., PMID:39358557
The active ingredient of Evodia rutaecarpa reduces inflammation in knee osteoarthritis rats through blocking calcium influx and NF-κB pathway., PMID:39434543
Targeted hematopoietic stem cell depletion through SCF-blockade., PMID:39473008
Cost-Effective DNA Storage System with DNA Movable Type., PMID:39555674
GALNT6, transcriptionally inhibited by KLF9, promotes osteosarcoma progression by increasing EFEMP1 expression via O-glycosylation modification., PMID:39581475
Dual blockade of IL-17A and IL-36 pathways via a bispecific antibody exhibits enhanced anti-inflammatory potency., PMID:39600699
Fc Effector Function of Immune Checkpoint Blocking Antibodies in Oncology., PMID:39663733
A humanized anti-MSLN×4-1BB bispecific antibody exhibits potent antitumour activity through 4-1BB signaling activation and fc function without systemic toxicity., PMID:39806351
Tensile force promotes osteogenic differentiation via ephrinB2-EphB4 signaling pathway in orthodontic tooth movement., PMID:39844202
Silibinin, a PLC-β3 inhibitor, inhibits mast cell activation and alleviates OVA-induced asthma., PMID:39870013
The Dose-Dependent Effects of Fluorocitrate on the Metabolism and Activity of Astrocytes and Neurons., PMID:40002432
Fc-competent TIGITx4-1BB bispecific antibody exerts potent long-lasting antitumor activity by potentiating CD8+ T cell activity and Fcγ receptor-mediated modulation of the tumor microenvironment., PMID:40010766
Blockade of αvβ6 and αvβ8 integrins with a chromogranin A-derived peptide inhibits TGFβ activation in tumors and suppresses tumor growth., PMID:40055773
Suppression of NF-κB and downstream XBP1 by DcR3 contributes to a decrease in antibody secretion., PMID:40073262
Maplirpacept: a CD47 decoy receptor with minimal red blood cell binding and robust anti-tumor efficacy., PMID:40078999
FcγRIIB (CD32B) antibodies enhance immune responses through activating FcγRs., PMID:40089806
New soluble CSF-1R-dimeric mutein with enhanced trapping of both CSF-1 and IL-34 reduces suppressive tumor-associated macrophages in pleural mesothelioma., PMID:40101804
Attenuation of cardiac ischemia/reperfusion injury via the decoy receptor DcR2 by targeting the PLAD domain of the death receptor DR5., PMID:40154678
Potential of recombinant CAV1-Fc in the treatment of ApxI toxin-induced damage by Actinobacillus pleuropneumoniae., PMID:40215801
In vivo screen of Plasmodium targets for mosquito-based malaria control., PMID:40399670
For research use only. Not for human or drug use.
